Catheter Precision (NYSEAMERICAN:VTAK) Shares Down 16.8% – Should You Sell?

Catheter Precision, Inc. (NYSEAMERICAN:VTAK)’s share price traded down 16.8% on Thursday . The stock traded as low as $1.03 and last traded at $1.14. 4,810,220 shares changed hands during mid-day trading, a decline of 76% from the average session volume of 20,025,498 shares. The stock had previously closed at $1.37.

Catheter Precision Stock Down 30.7%

The stock’s fifty day simple moving average is $0.92 and its 200-day simple moving average is $1.32. The stock has a market cap of $2.85 million, a P/E ratio of -0.06 and a beta of -1.07. The company has a debt-to-equity ratio of 0.35, a quick ratio of 0.06 and a current ratio of 0.06.

Catheter Precision (NYSEAMERICAN:VTAK) last announced its earnings results on Monday, May 18th. The company reported ($1.39) EPS for the quarter, topping the consensus estimate of ($20.90) by $19.51. Catheter Precision had a negative net margin of 1,297.56% and a negative return on equity of 76.51%. The company had revenue of $0.43 million for the quarter, compared to analysts’ expectations of $1.60 million.

Hedge Funds Weigh In On Catheter Precision

A hedge fund recently bought a new position in Catheter Precision stock. Millennium Management LLC bought a new stake in shares of Catheter Precision, Inc. (NYSEAMERICAN:VTAK) in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor bought 34,721 shares of the company’s stock, valued at approximately $64,000. Millennium Management LLC owned 2.08% of Catheter Precision as of its most recent filing with the Securities and Exchange Commission. Institutional investors and hedge funds own 20.34% of the company’s stock.

About Catheter Precision

Catheter Precision, Inc (NYSE American: VTAK) is a medical device company specializing in the design, development and manufacture of catheter-based products for interventional cardiology and peripheral vascular procedures. The company’s core business centers on balloon catheter platforms, offering both standard and specialty catheter configurations that address applications ranging from percutaneous transluminal angioplasty (PTA) to percutaneous transluminal coronary angioplasty (PTCA). Catheter Precision’s product portfolio is engineered to meet diverse clinical needs, including high-pressure dilation, scored and cutting balloon therapies, and drug-coated balloon delivery.

All of Catheter Precision’s products are developed in its ISO 13485-certified, FDA-registered manufacturing facility in Bloomington, Minnesota.